Zemiglo

Zemiglo

Manufacturer:

LG Chem Life Sciences

Distributor:

DKSH
Concise Prescribing Info
Contents
Gemigliptin tartrate sesquihydrate
Indications/Uses
Adjunct to diet & exercise in adults w/ type 2 DM. As monotherapy or in combination w/ metformin as initial therapy in treatment in naive patients w/ inadequate glycemic control by diet & exercise; in patients w/ inadequate glycemic control w/ maximal tolerated dose of metformin alone. In combination w/ metformin & sulfonylurea in patients w/ inadequate glycemic control w/ the maximal tolerated dose of metformin & sulfonylurea dual therapy. In combination w/ insulin (w/ or w/o metformin) in patients w/ inadequate glycemic control w/ stable dose of insulin.
Dosage/Direction for Use
Adult Max daily recommended dose: 50 mg once daily.
Administration
May be taken with or without food.
Contraindications
History of serious hypersensitivity reactions ie, angioedema or anaphylaxis, to another dipeptidyl peptidase-4 (DPP-4) inhibitor. Type 1 diabetes or diabetic ketoacidosis.
Special Precautions
Do not use in patient w/ history of hypersensitivity; w/ type 1 DM, diabetic ketoacidosis, severe infection or accident-related severe injury. Avoid use w/ alcohol beverage. Not recommended in patients w/ NYHA Class II-IV cardiac status. History of pancreatitis. Concomitant use w/ drugs known to cause hypoglycemia ie, sulfonylurea or insulin. Consider discontinuation of treatment in possible severe joint pain. Not recommended during pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Hypoglycemia, hypersensitivity reactions, dyspepsia.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH06 - gemigliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Zemiglo FC tab 50 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in